Three months after the first GLP-1 tablet for weight loss reached the market, a second one arrived, and it solves the problem the first one did not.
What happened
On 1 April 2026 the FDA approved orforglipron, which Eli Lilly sells as Foundayo, according to the company's announcement. It is approved for adults with obesity, and for some adults with overweight who also have weight-related medical problems, to reduce excess body weight and maintain that reduction long term, alongside a reduced-calorie diet and more physical activity.
It comes as tablets of 0.8, 2.5, 5.5, 9, 14.5 and 17.2 mg, taken once a day.
The evidence comes from the ATTAIN phase 3 programme, which enrolled more than 4,500 people. In ATTAIN-1, over 72 weeks, people on the highest dose lost 27.3 pounds, or 12.4% of their body weight, against 2.2 pounds, or 0.9%, on placebo. Across everyone who took it at any dose the figure was 25 pounds, or 11.1%, against 5.3 pounds, or 2.1%, on placebo.
Why "any time of day" is the headline
Orforglipron is a small molecule rather than a peptide. That is chemistry, and it would be a footnote except for what it means at breakfast.
Peptides are fragile in the gut. Oral semaglutide has to be taken on an empty stomach with a small sip of water, and nothing else may follow for a set time, or absorption falls away. In practice that means building a morning around a tablet.
A small molecule survives digestion without that scaffolding. Foundayo can be taken with food or without it, at whatever hour suits, and it is the only GLP-1 pill for weight loss that can. For anyone whose mornings are not their own, that is the difference between a medicine you take and a medicine you keep forgetting.
The number is lower, and that matters for your plate
Be clear about the trade. Around 12% at the top dose over 72 weeks is less than the 16.6% that oral semaglutide produced in its trial, and well short of the 20%-plus that tirzepatide reaches in head-to-head work. This is a convenient GLP-1, not the strongest one.
For eating, that cuts both ways. Less appetite suppression means a day with more room in it, which makes a protein floor easier to reach and makes nausea less likely to take a meal away from you. It also means the deficit has to come from somewhere other than the medicine doing the work for you.
The side effect list is the class list: nausea, constipation, diarrhoea, vomiting, indigestion, abdominal pain, headache, bloating, fatigue, belching, heartburn, wind, and hair thinning. Constipation is the one worth planning for from day one rather than treating in week three.
What it means for you
If you have been waiting for a GLP-1 that does not need a needle or a rulebook, this is it. Ask your prescriber how the expected result compares with what you are on now, or what you were considering, and make the trade deliberately rather than by default.
What to do with this
Different medicines leave different amounts of room in a day, and that room is what a plan has to be built inside. Put yours in and see the difference.